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Abstract 
Master thesis in Medicine: Phospholipid antibodies in the cerebrospinal fluid and 
serum, in SLE patients with suspected CNS involvement and associations with 
depression and cognitive impairment. 	
 
Sofia Linsten, 2014, department of Rheumatology and Inflammation Research, 
Sahlgrenska University hospital, Gothenburg, Sweden	
 
Introduction 
A broad spectrum of neuropsychiatric symptoms is common among SLE patients 
(NPSLE) as well as patients affected by Anti-phospholipid-syndrome (APS). 
Indicating a connection between neuropsychiatric illness and presence of anti 
phospholipid antibodies (aPLs) in patient's sera. 	
 
Aims 	
Examine if it’s possible to improve diagnosis of NPSLE patients by testing 
cerbrospinalfluid (CSF) for cardiolipin and β2-glycoprotein1 IgG antibodies. 
Investigate if aPLs presence in CSF and/or serum associates with cognitive 
impairment and depression. 	
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Methods 
CSF was collected from 51 SLE patients with neuropsychiatric involvement. Patient’s 
serological values of phospholipid antibodies (LA, aCL, aβ2GP1) were obtained by 
retrospective inspection of medical records. Comprehensive screening of depression 
and cognitive impairment was performed. Chi square test and Fischer’s exact test was 
used to calculate association between aPLs positivity, depression and cognitive 
impairment. 	
 
Results 
None of the patients were CSF positive for aCL or aβ2GP1. 27% were positive in 
serum for at least one aPLs. 59% suffered from depression. 45% suffered from 
cognitive impairment. Most common cognitive impairment was linguistic designation 
difficulties. Association between aPLs positivity and impaired linguistic designation 
was significant when including limit values for β2GP1 (p= 0.032). There was no 
association between aPLs positivity and depression or global cognitive impairment (p 
>0.05)	
 
Discussion and conclusions 
Diagnosis was not improved by testing CSF for aCL and aβ2GP1 IgG antibodies. 
Depression and cognitive impairment is common under diagnosed in NPSLE patients. 
It’s therefore important to continuously screen SLE patients for these conditions, 
regardless of aPLs positivity, although an association between serological aPLs 
presence and impaired linguistic designation is possible.	
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Introduction  
SLE 
Systemic Lupus Erythematosus SLE, often referred to as lupus, Latin for wolf, is a 
chronic systemic inflammatory autoimmune disease that can affect virtually all body 
organs. Disease activity and severity varies significant between affected individuals. 
Most frequently affected organs are joints, skin, kidneys, serous membrane (pleura, 
pericardium), blood cells (hemolytic anemia, leukopenia, lymphopenia, 
thrombocytopenia), blood vessels and the central and/or peripheral nervous system. 
SLE is characterized by alternating periods of active and latent disease. Associated 
symptoms such as fatigue, weight loss, fever, alopecia and sensitivity to sunlight are 
common. Diagnosis is based on clinical symptoms, -involving at least two different 
organ-systems, with the support of associated laboratory findings. Important 
laboratory findings is the presence of autoantibodies against DNA, nuclear material 
and other proteins, including anti-phospholipid antibodies (1). Lupus systemic nature 
and its wide spectrum of clinical symptoms, which often mimic those of other 
diseases, make Lupus hard to define and diagnose. A diagnostic aid is the criteria of 
the American College of Rheumatology updated 1982 and 1997. The ACR criteria are 
standard for the definition of SLE in clinical studies (2, 3) (Table 1).	
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Table 1. 1997 Update on revised SLE classification criteria defined by American 
collage of rheumatology. Four of eleven criteria are mandatory for SLE classification 
in clinical studies. The criteria have 96% clinical sensitivity and specificity. (2, 3) 
 
Criterion: Definition: 
1. Malar rash Fixed malar erythema over the malar 
eminence, flat or raised, tending to spare 
the nasolabial folds. 
2. Discoid rash Raised erythematosus patches with 
adherent keratotic scaling and follicular 
plugging’s, atrophic scaring may occur 
in older lesions. 
3. Photosensitivity Skin rash as un unusual reaction after 
exposure to sunlight.  
4. Oral ulcers Oral or nasopharyngeal ulcerations 
5. Non-erosive arthritis Involving two or more peripheral joints, 
characterized by tenderness, swelling, or 
effusion.  
6. Serositis Pleuritis or pericarditis 
7. Renal disorder  
Persistent proteinuria > 0.5 grams per 
day or > than 3+ if quantitation not 
performed 
OR 
Cellular casts--may be red cell, 
hemoglobin, granular, tubular, or mixed 
8. Neurological disorder 
Seizures--in the absence of offending 
drugs or known metabolic derangements; 
e.g., uremia, ketoacidosis, or electrolyte 
imbalance 
OR 
Psychosis--in the absence of offending 
drugs or known metabolic derangements, 
e.g., uremia, ketoacidosis, or electrolyte 
imbalance 
	 8
9. Hematologic disorder Hemolytic anemia--with reticulocytosis 
OR 
Leukopenia--< 4,000/mm3 on ≥ 2 
occasions 
OR 
Lyphopenia--< 1,500/ mm3 on ≥ 2 
occasions 
OR 
Thrombocytopenia--<100,000/ mm3 in 
the absence of offending drugs 
10. Immunologic disorder Anti-DNA: antibody to native DNA in 
abnormal titer 
OR 
Anti-Sm: presence of antibody to Sm 
nuclear antigen 
OR 
Positive finding of antiphospholipid 
antibodies on: 
An abnormal serum level of IgG or IgM 
anticardiolipin antibodies, 
A positive test result for lupus 
anticoagulant using a standard method, 
or 
A false-positive test result for at least 6 
months confirmed by Treponema 
pallidum immobilization or fluorescent 
treponemal antibody absorption test 
11. Positive Antinuclear antibody  An abnormal titer of antinuclear 
antibody by immunofluorescence or an 
equivalent assay at any point in time and 
in the absence of drugs 
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Epidemiology 
SLE has a strong female dominance and about 90 % of the affected is women in 
reproductive age of 15-40 years. However, the disease can affect both sexes and all 
ages. The average age of diagnosis is between 35-45 years. Worldwide disease 
incidence varies approximately between 1-11/100 000 of the population a year. The 
variation is depending on the study design, the method used for diagnostic, time span 
and the country where the study was preformed (1). Earlier Swedish studies 
performed between 1981-1991 shows an overall incidence of approximately 4.8/100 
000 and a prevalence about 36-68/100 000 (4-6).  
  
	 10
Pathogenicity and treatment 
Disease pathology is highly complex, multifactorial and not yet fully understood. 
Dysfunction in the cell mediated and the humoral mediated immune system are 
believed to contribute to disease development. Errors in apoptotic pathways and 
altered antigen presentation as well as abnormalities in B and T cells development and 
function, leads to production of inflammatory cytokines and autoantibodies against 
nuclear acid and its binding proteins. Immune complex is formed when 
autoantibodies binds to self-tissue antigens. Accumulation of these immune 
complexes wrongly activates the complement system and causes multi organ 
inflammation and damage (7, 8). Lupus can most likely be triggered by both 
environmental and genetic factors. A first-degree relative with one or more 
autoimmune diseases increase the risk of disease development (9). SLE disease 
development concordance is 25% in monozygotic twins compared to 2 % in dizygotic 
twins (10). Established environmental risk factors are endogen and exogenous 
exposure to estrogens, especially 16alfahydroxyesteron, exposure to UV light, current 
smoking and medications e.g. procainamide, hydralazine. Lupus is treated with 
immunosuppressive therapy, anti-inflammatory drugs, anti-malarias, and steroids (1). 	
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Late complications 
Effective treatment and better diagnostic methods have reduced mortality associated 
with acute disease activity. However, the increased mortality rate among SLE patients 
is today mainly caused by late complications in form of cardiovascular disease 
(CVD). SLE patients has an increased susceptibility to develop atherosclerosis, often 
affecting the coronary arteries and in addition of traditional risk factors (11-13). A 
Swedish cohort from Gustafson et al (13) found aPLs presence a predictive risk factor 
for cardio vascular mortality (CVM) in SLE patients. A bright spot is that treatment 
with anti malaria agent. Besides the drugs direct effect on SLE activity, it also have 
vascular protective features, as they are believed to normalize lipid and glucose level 
and decreases the risk of thrombosis (1). 	
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NPSLE 
Neuropsychiatric Systemic Lupus Erythematosus, NPSLE, is when the systemic 
disease, focal and/or diffuse affects the central and/or the peripheral nervous system. 
Neuropsychiatric manifestations are common in SLE patients and its frequency varies 
between 12-95%. The broad variation in frequency is mainly due to differences in 
study design and a diagnostic inclusion criterion’s used to define NPSLE (1). The 
Neuropsychiatric symptoms vary from mild cognitive dysfunction, anxiety and 
depression, to manifestations such as stroke, psychosis and seizures (14). In 1999 the 
American College of Rheumatology (ACR) ad Hoc committee developed an 
extensive standardize nomenclature system that define 19 NPSLE syndromes (15) 
(Table 2). The ACR criteria are today standard for describing NP events in clinical 
studies (1). Cognitive dysfunction and mood disorders are two of the most frequent 
NP-syndromes affecting approximately 20% of NPSLE patients (1, 14, 16, 17).	
 
Table 2. Neuropsychiatric syndromes in SLE defined by the American collage of 
rheumatology (18). 
 
 
  
  
1. Acute Confusional State 11. Mood disorders 
2. Acute inflammatory demyelinating 
Polyradiculoneuropathy (Gillian Barre 
syndrome) 
12. Movement disorders (Chorea) 
3. Anxiety Disorder 13. Myasthenia Gravis 
4. Aseptic Meningitis 14. Myelopathy 
5. Autonomic disorder 15. Neuropathy, Cranial 
6. Cerebrovascular disease 16. Plexopathy 
7. Cognitive dysfunction 17. Polyneuropathy 
8. Demyelinating syndromes 18. Psychosis  
9. Headache 19 Seizures and Seizure Disorders 
10. Mononeuropathy single/multiplex  
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Pathogenesis  
NPSLE pathogenicity remains unclear and not yet fully understood. 
Microvasculopathy, thrombosis, autoantibodies, inflammatory mediators and blood 
brain barrier dysfunction are believed to contribute to disease development (19). 
Growing evidence supports that several different autoantibodies, especially when they 
gain access to CSF and brain tissue play an important role in disease development. A 
frequently cited study performed by Giorgio et al, (20) showed that Lupus antigens 
(anti-DNA-antibodies) cross react with DNA receptors as well as neural glutamate 
binding- N-methyl-D-aspartate (NMDA) receptor subunits, NR2a and NR2b. Auto 
binding to NMDA induces neuronal apoptosis, provides access to CSF and mediates 
non-thrombotic and non- vascular abnormalities in the central nervous system. 
NMDA subunit antibodies and its neurotoxicity were later observed in CSF from a 
SLE patient with cognitive impairment. Kowal et al. (21, 22) proved that an 
intracranial injection of anti NMDA receptor antibodies in mice caused apoptosis of 
hippocampus and causes cognitive impairment. Results from Yoshio et al. (23) 
indicate that glutamate NR2 rec antibodies in CSF may be more accurate then serum 
samples when diagnosing NPSLE. Several other studies show a strong association 
between NPSLE and persistent presence of phospholipid antibodies (aPLs) in serum. 
Elevated serum titers of aPLs are believed to be a risk factor for NPSLE development 
(14).	
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Diagnostic methods and treatment 
It`s often a long process before a patient gets diagnosed with NPSLE. First the 
physician needs to exclude and treat other non-SLE related causes. Then clarify if the 
neuropsychiatric symptoms are due to SLE-mediated organ dysfunction or infection, 
medication side effects or metabolic abnormalities. Clinical examination, laboratory 
analyzes of serum and CSF samples as well as neuroimaging, preferably MRI are 
helpful tools (14). CSF abnormalities in NPSLE patients include; pleocytos and/or 
mild elevated protein levels, increased intrathecal synthesis of immunoglobulin’s 
and/or oligoclonal bands, elevated levels of pro-inflammatory cytokines iL6, IL8 as 
well as elevated levels of astroglial degradation products (24-27). Although there is 
no single specific test method to diagnose NPSLE, there is a huge need for such a 
method. NPSLE is considered one of the most serious manifestations of SLE, leading 
to both increased morbidity and mortality in SLE patients (28-31). Treatment depends 
on pathogenicity. Symptomatic treatment is used in addition when necessary. Primary 
NPSLE without presence of aPLs is treated with immunosuppressive therapy, manly 
cyclophosphamide (14, 19).	
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Anti phospholipid antibodies and clinical features 
Phospholipids function as building blocks in various organelles and cellular 
membranes. Phospholipid antibodies (aPLs) can react with complexes of 
phospholipids and plasma proteins such as Beta2 Glycoprotein1 (aβ2GP1), 
prothrombin, annexin V, protein C and protein S. aPLs can mediate thrombosis 
development by inhibit natural anti coagulant system (protein C and S), impair 
fibrinolysis or trough direct impact on cellular functions. In addition to thrombosis 
development aPLs may also bind directly to brain tissue cells and endothelial cells. 
The reactions trigger a cascade of neuroinflammatory responses that undermine the 
protective function of the blood brain barrier. (1). A different isotype of aPLs was 
found in CSF, compared to serum in a study involving patients suffering from 
psychosis. This finding might indicate a possible intrathekal production of 
phospholipid antibodies during neuropsychiatric disease (32). Stojanovich L et al. 
(33) showed an association between the positivity of aPLs and several non-thrombotic 
neurological manifestations.  
aPLs are present in approximately 1-5% of the general asymptomatic healthy 
population, with a higher frequency among the elderly population (34, 35). Infections, 
neoplasm, active vaccination and drug therapies are known to cause elevation of these 
autoantibodies (34, 36-39). Anti phospholipid syndrome (APS) is when persistent 
presence of aPLs causes clinical symptoms, defined as one or more event of vascular 
thrombosis and/or pregnant morbidity. aPLs used to diagnose APS are Lupus 
anticoagulant (LA), anti-cardiolipin (aCL) and anti- Beta2Glycoprotein1 (aB2GP1) 
(40). 	
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Anti Phospholipid Syndrome (APS)  
APS is when persistent presence of aPLs causes clinical symptoms. It is an 
autoimmune disease that can cause thrombosis in both arteries and veins and in all 
vessel sizes and organs. It can also cause thrombocytopenia, severe pregnancy 
morbidity and neurological disease. Primary APS, independent of other diseases 
occur, but APS is often linked to other autoimmune diseases particularly SLE (1). 
Approximately 36% of SLE patients suffer from secondary APS (41). Diagnosis is 
based on clinical symptoms as vascular thrombosis and/or pregnancy morbidity and 
positive serological test for at least one phospholipid antibody: Positive test for lupus 
anticoagulants (LA), medium or high titers for Beta2 glycoprotein 1 (aβ2GP1) IgG or 
IgM antibodies, or medium or high titers of Cardiolipin (aCL) IgG or IgM antibodies, 
with a positive persistence over 12 weeks (40, 42, 43). Estimated incidence of APS is 
about 5/100.000 persons a year and the prevalence varieties between 40-50/100.000 
(40). Neuropsychiatric illness is common in APS patients (44, 45). APS related 
neuropsychiatric symptoms vary from transient ischemic attack (TIA) and stroke to 
epileptic seizures, depression, impaired cognition, headaches and psychosis (41, 46). 
Anti phospholipid syndrome with clinical manifestations is treated with life long anti 
coagulant therapy, mainly Warfarin (47-49). 	
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Scientific issue 
A variety of neurological and psychiatric manifestations are linked to the presence of 
aPLs in the patient's sera. There is a strong comorbidity between SLE and APS and 
both diseases can cause neuropsychiatric symptoms (50-52). With current available 
diagnostic methods it’s impossible to determinate the true pathogenesis of 
neuropsychiatric symptoms in a SLE patient especially when suffering from 
secondary APS. Treatment is therefore often directed against both diseases, with 
anticoagulation- and immunosuppressive therapy. Another major difficulty is to 
discern whether the cognitive impairment and/or depression are due to immunological 
reactions in the brain caused by antibodies, or whether it is a result of living with a 
difficult chronic disease. 	
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Aims 
 
1. Examine if it’s possible to improve diagnosis of SLE patients with suspected CNS 
involvement and possible serological aPLs positivity (LA, aCL, β2GP1) by testing 
CSF for Cardiolipin and β2-glycoprotein1 IgG antibodies. 	
 
2. Investigate if the CSF-titers and/or serum titers of anti-phospholipid antibodies in 
NPSLE patients associates with cognitive impairment and/or depression. 	
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Materials and Methods 
Study population 
Cerebrospinal fluid (CSF) samples were collected from 51 consent SLE patients at 
Sahlgrenska University hospital, rheumatology clinic in Gothenburg, Sweden 
between 2011-2013. All patients included in the study were previously diagnosed 
with SLE according to at least 4 ACR/SLE criteria and suffered from CNS 
involvement according to at least one ACR/NPSLE criteria. Of these, 16 patients 
suffered from depression and 10 suffered from cognitive impairment, according to 
ACR at the start of the study. The participants, 6 men and 44 women were aged 20-71 
years old, the average age was 40 years old and had an average disease duration of 8,5 
years. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and 
Systemic Lupus International Collaborating Clinics (SLICC) were used to estimate 
the SLE disease activity and chronic damage. 
 
Serum samples  
Serum samples of phospholipid antibodies (LA, aCL, aβ2GP1) were collected and 
analyzed earlier for diagnostic purpose during the 51 patient’s hospitalization. Serum 
test result and titers were obtained by retrospective inspection of medical records.  
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CSF laboratory analyses 
The collected CSF samples were kept frozen at -70 C until assayed, according to 
customary routines used at SU clinical immunology and transfusion medicine. CSF 
analyses of aCL and aβ2GP1 were performed with an automatic enzyme-linked 
immunosorbent assay (ELISA) based method (Alegria from Orgentec Diagnostica 
GmbH). All analyses were performed in accordance with the manufacturer’s 
instructions.  
The Sensotronic Memorized Calibration (SMC) technology is a method based on an 
indirect enzyme immunoassay reaction. The test consists of 8 barcode labeled strips. 
Each strip is designed for one antigen and consists of enzyme conjugate, enzyme 
substrate, sample dilution buffer and a quality check. 10μl CSF sample was added to 
each strip. The samples were incubated, washed with conjugate and washed again. 
Substrate was added and triggered a hydrolyzing process. The test result was 
measured spectrophotometrically, as a blue color shift according to the amount of 
antibodies in the sample occurred.  
Positive controls for aCL and aβ2GPI sera were run in the same assay as CSF samples 
to confirm specificity of the results. The manufactures reference range and limit 
values based on serum samples was used to determinate aCL and aβ2GP1 positivity. 
Reference range 
aCL IgG units/ml: Values below 10 units /ml was considered negative and values at 
10 units/ml and over, were considered positive (53). 
aβ2GP1 IgG units/ml: Values below 5 units/ml were considered negative, values 
between 5-9 units/ml were considered limit values and values at 10 units/ml and over 
were considered positive (53).  
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Depression and cognitive impairment 
Screening of depression and cognitive impairment was performed by experienced 
nursing staff at Sahlgrenska University hospital. To detect possible depression, study 
protocol included two depression surveys; the Montgomery–Åsberg Depression 
Rating Scale (MADRS) and Patient Health Questionnaire-9 (PHQ-9) and one general 
screening for neuropsychiatric disease, The Mini International Neuropsychiatric 
Interview (MINI). The patients were classified as depressed if they were rated 
depressed (mild-sever) at one of these three screening tests. To detect possible 
cognitive impairment, we used the cognitive screening battery (KSB in Swedish), 
correspondent to the cognitive assessment battery (CAB in English). The test is 
designed in accordance with the recommendations of the American Academy of 
Neurology (AAN). The cognitive assessment battery is a sensitive and specific test 
that measures performances in several cognitive functions as: Speed and attention, 
episodic memory and learning, visuospatial function, language and executive function 
(54). Test results were assessed on the basis of age-averages normal value for healthy 
individuals. Performances of 1.5 standard deviations (SD) below average age were 
classed as pathological, in accordance with test protocol (55). Patients who scored 1.5 
SD below average age in at least one of the 6 cognitive tests were considerate 
cognitive impaired and referred to as global cognitive impaired. The subject’s 
cognitive impairment was classified as mild, moderate or severe, based on the number 
of impaired domains (1-.2, mild; 3-4, moderated; severe >5).  
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Statistical methods 
Statistical Package for Social Sciences, SPSS (version 22) was used to calculate the 
statistic results. 
The participants were divided in to two subgroups according to if they were serum 
positive for at least one of the tree aPLs, or aPLs serum negative. Calculations 
including limit values for aβ2GP1 in the positive group respectively in the negative 
group were performed.  
Chi square test and Fischer’s exact test was used to calculate possible association 
between aPLs serum positivity, depression and cognitive impairment. Two sided P 
values <0.05 was considered significant. 
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Ethics 
Our study is a part of a larger study that examines neuropsychiatric symptoms in SLE 
patients. Ethical license number Dnr 433-11, approved 2011-07-05.  Study 
participation is completely anonymous and voluntary. All participants are given both 
verbal and written information about study aims and design prior consent. Participants 
may at any time, without explanation, terminate their participation in the study, and/or 
request that their samples be destroyed.  
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Results 
Our aim was to examine if CSF phospholipid antibody testing could improve the 
diagnosis of NPSLE patients. We also wanted to see if phospholipid antibodies in 
NPSLE patients were associated with cognitive impairment and/or depression. 
 
CSF 
None of the patients were CSF positive for phospholipid antibodies (aCL or aβ2GP1). 
All CSF samples analyzed in the study were well below the serum threshold limit 
values.  
Serum 
Retrospective review of medical records showed that; 14 (27%) of the 51 NPSLE 
patients were aPLs positive in serum. 11 (22%) were positive for Cardiolipin 
antibodies (aCL). 7 (14%) were positive for- and 3 (6%) hade limit values of Beta2- 
glycoprotein antibodies (aβ2GP1). 9 (18%) were positive for Lupus anticoagulation 
(LA). 5 (10%) patients were positive for 2 antibodies. 3 (6%) of the patients were 
positive for all three antibodies, so-called triple positive (Table 3). 
Table 3 Frequency of serological aPLs positivity and limit values in study population. 
 aPLs  aCL aβ2GP1 LA Double Triple  
Positive 14 (27%) 11 (22%) 7 (14%) 9 (18%) 5 (10%) 3 (6%) 
Limit   3 (6%)    
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Cognitive impairment 
23 patients (45%) suffered from some sort of cognitive impairment, compared to 10 
(20%) cognitive dysfunctional patients diagnosed according to ACR criteria at study 
entry (table 6). 12 patient (23%) suffered from mild cognitive impairment and 11 
patients (22%) from moderate cognitive impairment, none of the patients suffered 
from sever cognitive impairment. Most common cognitive impairments were; 
linguistic designation- and speed and attention difficulties (table 4). A higher 
percentage of the aPLs positive patients suffered from some type of cognitive 
impairment compared to aPLs negative patients, but the difference was not significant 
(Table 5 and 6). The association between aPLs positivity and impaired linguistic 
designation was significant when including limit values for B2GP1 (p=0.032)  
(Table 7). 
Table 4 Screened frequency of Cognitive impairment in study population according to 
the Cognitive assessment battery (CAB). 
 Total 
n=51 
aPLs positive  
n=16 
aPLs negative 
n=35 
Learning and 
episodic memory 
4 (8%) 1 (6%) 3 (9%) 
Speed attention 12 (23%) 5 (31%) 7 (20%) 
Linguistic 
designation 
16 (31%) 8 (50%) 8 (23%) 
Spatial functions 5 (10%) 1 (6%) 4 (8%) 
Linguistic 
functions (token): 
6 (12%) 3 (19%) 3 (6%) 
Executive function 10 (20%) 4 (25%) 6 (12%) 
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Depression  
30 patients 59% suffered from depression (mild-sever) according to at least one 
screening survey, compared to 16 (31%) patients diagnosed with mood disorder 
according to ACR criteria at study entry (Table 6). There was no significant 
association between depression and aPLs positivity. A higher percentage of aPLs 
negative patients suffered from depression compared to aPLs positive patients, but the 
difference was not significant (table 5 and 6). 
  
	 27
Table 5. Clinical characteristic of study NPSLE patients with and without serological 
aPLs positivity, including limit values for aβ2GP1in the positive group.  
*Cognitive dysfunction (CD) *Cerebrovascular disease (CVD)  
  
 aPLs positive n=16 aPLs negative n=35 
Average age 37,8 41,8 
Gender 16 females  
0 males 
29 females  
6 males 
Average years 
with SLE 
11,6  9,9 
Most frequent 
ACR/NPSLE 
syndrome at 
study entry 
 
Mood disorders: 5 (31%) 
 
Headache: 3 (19%) 
 
CD*: 3 (19%) 
 
CVD*: 3 (19%) 
 
Mood disorders: 11 (31%) 
Headache: 8 (22%) 
 
CD*: 7 (20%) 
 
Cranial Neuropathy: 5 (14%) 
 
Average SLE 
damage index 
(SLICC) 
1,3 1,4 
Average 
Disease 
activity 
(SLEDAI) 
8,6 8,6 
Number of 
patients with 
cognitive 
impairment 
(CAB) 
9 (56%) 14 (40%) 
Number of 
patients with 
depression 
(MADRAS, 
PHQ9, MINI) 
8 (50%) 22 (63%) 
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Table 6. Shows the number of patients with Mood disorder or cognitive dysfunction 
according to ACR criteria’s compared to the number of patients with depression or 
cognitive impairment found in our screening. 
 Total n= 51 aPLs positive n=16 aPLs negative n=35 
ACR Mood 
disorder * 
16 (31%) 5 (31%) 12 (34%) 
Screened 
number of 
patients with 
depression  
30 (59%) 8 (50%) 22 (63%) 
ACR Cognitive 
dysfunction * 
10 (20%) 3 (19%) 7 (20%) 
Screened 
number of 
patients with 
cognitive 
impairment  
23 (45%) 9 (56%) 14 (40%) 
* Number of patients diagnosed according to ACR at study entry.  
Our screening showed a higher prevalence of cognitive impairment and depression in 
the study population than expected, when compared to patients diagnosed with 
cognitive dysfunction and mood disorder according to ACR/NPSLE criteria at study 
entry. Indicating that depression and cognitive impairment is under diagnosed among 
SLE patients with CNS involvement. 
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Statistical result 
There was no association between CSF or serological aPLs positivity (s-aPLs) and 
depression or global cognitive impairment (p >0.05). When included serological 
B2GP1 limit values (5-9 units/ml) as aPLs positive instead of aPLs negative, we 
found an association between serological aPLs positivity and cognitive linguistic 
designation (p= 0.032) (Table 7) and (Figure 1). 
Table 7. Chi-Square tests show statistic association between serological aPLs 
positivity (including limit values for B2GP1) and cognitive linguistic designation 
impairment. 
 
 
 
 
 
  
 Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square ,032 ,020 
Fisher's Exact Test ,032 ,020 
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Figure 1.  
 
Shows association between serological aPLs positivity (including limit values for 
B2GP1 in the positive group) and cognitive linguistic designation impairment 
expressed in percent.  
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Discussion  
Several studies have proved connection between NPSLE manifestations and 
phospholipid antibodies in serum (56-58). Secondary APS due to SLE is common 
(41) and neuropsychiatric illness is common among APS patients as well (45). Today 
it’s routine to test for anti-phospholipid antibodies in serum when sudden onset of 
cerebral symptoms in SLE patients occur. Mainly to rule out thrombotic disease, as an 
important piece in the NPSLE and APS diagnostic puzzles. 	
 
Aim 1 
The results from previous studies testing anti-phospholipid antibodies in CSF are 
inconsistent. In our study we were not able to detect aCL or aB2GP1 IgG antibodies 
in CSF in any of our 51 subjects, although 14 of them were IgG aPLs positive in 
serum and 3 exhibited limit values for B2GP1. Our results are in accordance with 
result from a similar study performed by Jedryka-Goral et al. (59) Who also were 
unable to detect aCL in the CSF of NPSLE patients and healthy controls, even in sera 
aCL positive individuals. On the other hand, our results stand in contrast to results 
from Sokol et al. (32) and Martinez-Cordero et al. (60) Their results indicate that 
neuropsychiatric illness can cause intrathekal production of phospholipid antibodies, 
alternatively leakage of anti-phospholipid antibodies from systemic circulation to 
CSF, due to impaired blood brain barrier function. The diverse outcomes are probably 
due to the differences in study designs. The main differences are the composition of 
the study population, diagnostic criteria and inclusion/exclusions criteria. Most 
importantly is the different assay methods used to detect aPLs and its different limits 
of values that define (aPLs) positivity.  	
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It’s difficult to compare two similar groups, especially when the diagnosis is based on 
criteria as in SLE and NPSLE. The broad inclusion criteria that define disease 
positivity can give the study population a wide character. To improve our study 
design we need to include more patients, most importantly serological and CSF aPLs 
values from healthy controls and SLE patients without neuropsychiatric involvement. 
We also need to develop a normal range for aCL and aB2GP1 IgG antibodies in CSF 
and investigate if NPSLE patients CSF titers of these antibodies differences from CSF 
antibody titers in healthy controls and SLE patients without CNS involvement. 
Another improvement would be to collect and analyze CSF and serum samples for 
aPLs, IgM, IgG IgA at the same time and with the same analyze method. In our 
present study serum result was obtained by retrospective examination of medical files. 
This makes it impossible to determinate the type of analyze method used on the 
serological samples, as this is rarely noted. Different ELISA analyzes methods for 
detecting aCL and aB2GP1 are known to give varying results (61-64).  
NPSLE are a relatively rare diagnose. Our study strength is the relatively large study 
population of 51 individuals, compared to other NPSLE studies, often investigating 
smaller populations. Another strength is the extensive screening of depression and 
cognitive impairment. The data collected can be of great value in future studies.	
  
	 33
Aim 2 
Cognitive impairment and depression is two of the most frequent reported 
neuropsychiatric syndromes in SLE patients (65, 66). Our extensive screening of 
depression and cognitive impairment confirms that these conditions are highly 
prevalent and often under diagnosed in NPSLE patients (table 6). The reasons behind 
these findings are harder to interpret. Both depression and cognitive impairment can 
be caused by primary NPSLE, APS or several non-NPSLE or APS related causes. 
Comorbidity between depression and cognitive impairment exists and these factors 
make it hard to evaluate the results separately and estimate the true disease incidence. 
Another concern to consider when testing cognitive function in SLE patients is that 
the symptoms can be fluctuating and hard to detect in one single test opportunity, one 
or more follow up tests is therefore recommended. 	
We found no statistic association between aPLs presence and depression. A higher 
percentage of aPLs negative NPSLE patients suffered from depression compared to 
aPLs positive NPSLE patients. There is data that suggest a possible connection 
between LA positivity and depression (33). Gao et al. (67) showed a correlation 
between depression like behavior in mice and titers of autoantibodies against DNA, 
NMDA receptors and aCL. 	
Serological presence of phospholipid antibodies has been shown to contribute to 
impaired cognitive function. Performances requiring speed and attention, 
concentration and visuospatial functions appear to be particularly affected (56, 68, 
69). In our study we found a statistic association between cognitive linguistic 
designation impairment and aPLs positivity (p<0.032), although we only found 
significance when including limit values for β2GP1. 	
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There are several possible cofounders not yet taken to consideration that may 
contribute development of cognitive impairment. It’s possible that the prevalence of 
cognitive impairment increases with age. In our study the age of the population varied 
between 20-71 years, with a relatively low average age of 40 years, the average age 
was lower for aPLs positive 37,8 years respectively 41,8 years for aPLs negative. 	
Another cofounder is the number of years with SLE diagnosis, as more years with 
SLE could increase the risk of cognitive impairment. Longer period of multi organ 
inflammation, accelerated arteriosclerosis and medical treatment, including 
prednisolone, increases the risk. Although some data suggest that it is uncertain if 
corticosteroid use contributes to development of cognitive impairment in SLE patients 
(70, 71). The aPLs positive average age with SLE diagnosis was 1,7 year longer than 
aPLs negative individuals (table 5) theses differences could have affected our 
statistical outcome. Other possible cofounders are disease activity level (SLEDAI) 
and chronic damage level (SLICC). In our groups there was no difference in average 
disease activity 8,6 for both groups and chronic damage levels was also similar 1,3 for 
aPLs positive respectively 1,4 for aPLs negative (table 5). All above-mentioned 
cofounders need to be taken into account for and investigated further, suggestively by 
using statistical regression analyses in future studies. One can also discuss if our limit 
value for cognitive impairment, (results below average age in one of six cognitive 
tests) is too low and needs to be elevated to two test results below average age, to 
enhance the security that it is true cognitive impairment that is exanimated (72).  
Further more, aPLs presence in patient’s sera does not always cause clinical 
symptoms, including CNS involvement. We therefor need to consider the fact that the 
frequency of aPLs (1 -5%) among the healthy population without CNS involvement 
can affect our study outcome. It’s therefore mandatory in future studies to screen the 
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study population and control groups for possible cofounders such as infections, 
neoplasm, active vaccination and drug therapies since they may affect and increase 
aPLs values (34).  
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Conclusions 
How phospholipid antibodies gain access to CNS and affects neuropsychiatric 
functions remains a subject of investigation. It’s unlikely to improve diagnosis of SLE 
patients with neuropsychiatric involvement, by testing CSF for cardiolipin and β2-
glycoprotein1 IgG antibodies. Since all our CSF samples were negative, even when 
sera were positive. Although a larger study, in witch CSF and serological values are 
taken at the same time and in compression with a healthy controls and SLE patients 
without neuropsychiatric manifestations. As well as development of aCL and aβ2GP1 
CSF normal range values, must be performed before we can draw this conclusion 
with absolute certainty.  
Depression and cognitive impairment is common and often under diagnosed in 
NPSLE patients, regardless of aPLs positivity. Although an association between aPLs 
presence in serum and linguistic designation impairment is possible and needs to be 
exanimated further in future studies. 	
It is of great importance to continuously screen SLE patients with CNS involvement 
for depression and cognitive impairment in clinical practice. So that proper treatment 
can be initiated when needed and hopefully decrease morbidity and mortality in this 
patient group. 	
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Populärvetenskaplig sammanfattning på svenska 
Fosfolipidantikroppar i blod och ryggmärgsvätska, hos SLE-patienter med 
misstänkt CNS-engagemang och samband med depression och kognitiv 
nedsättning. 
 
Autoimmunitet är när kroppens immunförsvar som är till för att bekämpa infektioner 
och döda eller skadade celler, börjar angripa den egna kroppens friska vävnader. 
Autoimmuna sjukdomar är vanligt inom reumatologin, en av dessa är Systemisk 
Lupus Erytematosus (SLE), en kronisk sjukdom som ofta drabbar unga kvinnor. 
Symptom från hjärnan och centrala nervsystemet är vanligt vid SLE och kallas då 
Neuropsykiatrisk SLE (NPSLE). Depression samt svårigheter att utföra uppgifter som 
kräver minne, inlärning, tidsuppfattning, beslutsfattande samt numerisk och språklig 
förmåga, s.k. kognitiv nedsättning är vanligt vid NPSLE och orsakar lidande och ökad 
dödlighet. Idag finns ingen enskild säker metod att diagnostisera NPSLE. 
 
Vi undersökte förekomst av fosfolipidantikroppar i blod och ryggmärgsvätska hos 51 
frivilliga SLE patienter med symptom från centrala nervsystemet, i hopp om att kunna 
förbättra diagnostiken av NPSLE. Patienterna undersöktes också för förekomst av 
depression och tecken på kognitiv nedsättning, för att se om det fanns ett möjligt 
samband mellan dessa tillstånd och förekomst av fosfolipidantikroppar i blod 
och/eller ryggmärgsvätska.  
 
Ingen av patienterna visade förhöjda nivåer av fosfolipidantikroppar i 
ryggmärgsvätska, trotts att 14 av dem uppvisade förhöjda nivåer i blodet. Det gick 
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således inte att förbättra diagnostiken av NPSLE genom att testa ryggmärgsvätska för 
dessa antikroppar. 
 
Vi fann däremot att depression och kognitiv nedsättning är vanligt och ofta 
underdiagnostiserat bland NPSLE patienter. Det är därför viktigt att kontinuerligt 
undersöka SLE patienter för dessa tillstånd så att rätt behandling kan sättas in i tid och 
minska lidande och dödligheten hos denna ofta unga patientgrupp. Ett visst samband 
mellan förekomst av fosfolipidantikroppar i blod och kognitiv nedsättning är möjligt, 
men vidare forskning krävs innan vi kan dra några säkra slutsatser. 
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